4-[(1R,2R)-2-(2-naphthalen-2-yloxyethoxy)cyclohexyl]morpholine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-[(1R,2R)-2-(2-naphthalen-2-yloxyethoxy)cyclohexyl]morpholine
• 化学式: C₂₂H₂₉NO₃
• 分子量: 355.5
• InChiKey: GUACQORHQAFRFP-FGZHOGPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  30.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Uses of ion channel modulating compounds
  申请人：Beatch N. Gregory

  公开号：US20050026993A1

  公开（公告）日：2005-02-03

  Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.

  治疗或预防心律失常（包括治疗或预防心房颤动）的方法、制剂、给药方案和给药途径。在这些方法中，通过对受试者施用一种或多种离子通道调节化合物来治疗或预防疾病或病症，其中离子通道调节化合物可在受试者体内产生特定的血浆水平。离子通道调节化合物可以是环烷基胺醚化合物，特别是环己胺醚化合物。
• USES OF ION CHANNEL MODULATING COMPOUNDS
  申请人：Beatch Gregory N.

  公开号：US20080188547A1

  公开（公告）日：2008-08-07

  Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
• ION CHANNEL MODULATING ACTIVITY II
  申请人：Fedida David

  公开号：US20090270478A1

  公开（公告）日：2009-10-29

  Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
• US7820712B2
  申请人：——

  公开号：US7820712B2

  公开（公告）日：2010-10-26